We know that Nventa is very interested in applying HspE7 as a therapeutic vaccine to treat RRP, and this is the second itgeration of HspE7, with the new adjuvant.
Safety seems to have been established.
For more, see http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=
/www/story/01-14-2008/0004735554&EDATE
